Diabetes News

In previous First Word columns, I discussed the effects of SGLT2 inhibitors on the kidney to prevent progression of chronic kidney disease, congestive heart failure, CVD and overall mortality.

Healio has compiled a list of the most-read nephrology articles in 2024.

Healio has compiled a list of the most-read nephrology news stories related to diabetes and metabolic dysfunction in 2024.

Healio has compiled a list of the most-read nephrology news stories related to chronic kidney disease in 2024.

Healio has compiled a list of the most-read nephrology-related exclusive features in 2024.

Use of the dual SGLT1/SGLT2 inhibitor sotagliflozin was associated with similar HbA1c reduction for patients with type 1 diabetes using insulin whether or not they also had chronic kidney disease, according to study data.

The GLP-1 receptor agonist semaglutide may not only add another therapeutic option for chronic kidney disease, but it could also lead to changes in the way clinicians treat the condition.

SGLT2 inhibitors and GLP-1 were more effective than dipeptidyl peptidase-4 inhibitors and sulfonylurea kidney complications .

Canagliflozin was associated with increased iron utilization and improved hemoglobin levels for adults with type 2 diabetes and chronic kidney disease, according to data published in Nephrology Dialysis Transplantation.